JP2018529331A5 - - Google Patents

Download PDF

Info

Publication number
JP2018529331A5
JP2018529331A5 JP2018511416A JP2018511416A JP2018529331A5 JP 2018529331 A5 JP2018529331 A5 JP 2018529331A5 JP 2018511416 A JP2018511416 A JP 2018511416A JP 2018511416 A JP2018511416 A JP 2018511416A JP 2018529331 A5 JP2018529331 A5 JP 2018529331A5
Authority
JP
Japan
Prior art keywords
protein
amino acid
mutation
seq
acid residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018511416A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018529331A (ja
JP6975709B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/070654 external-priority patent/WO2017037196A1/en
Publication of JP2018529331A publication Critical patent/JP2018529331A/ja
Publication of JP2018529331A5 publication Critical patent/JP2018529331A5/ja
Application granted granted Critical
Publication of JP6975709B2 publication Critical patent/JP6975709B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018511416A 2015-09-02 2016-09-01 安定化したウイルスクラスi融合タンパク質 Active JP6975709B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562213466P 2015-09-02 2015-09-02
US62/213,466 2015-09-02
PCT/EP2016/070654 WO2017037196A1 (en) 2015-09-02 2016-09-01 Stabilized viral class i fusion proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020188363A Division JP2021045138A (ja) 2015-09-02 2020-11-12 安定化したウイルスクラスi融合タンパク質

Publications (3)

Publication Number Publication Date
JP2018529331A JP2018529331A (ja) 2018-10-11
JP2018529331A5 true JP2018529331A5 (enExample) 2019-08-08
JP6975709B2 JP6975709B2 (ja) 2021-12-01

Family

ID=56855456

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018511416A Active JP6975709B2 (ja) 2015-09-02 2016-09-01 安定化したウイルスクラスi融合タンパク質
JP2020188363A Pending JP2021045138A (ja) 2015-09-02 2020-11-12 安定化したウイルスクラスi融合タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020188363A Pending JP2021045138A (ja) 2015-09-02 2020-11-12 安定化したウイルスクラスi融合タンパク質

Country Status (7)

Country Link
US (2) US10538557B2 (enExample)
EP (2) EP3344288A1 (enExample)
JP (2) JP6975709B2 (enExample)
CN (1) CN108025057B (enExample)
AU (2) AU2016316723B2 (enExample)
CA (1) CA2997181A1 (enExample)
WO (1) WO2017037196A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10426829B2 (en) 2015-09-03 2019-10-01 Novavax, Inc. Vaccine compositions having improved stability and immunogenicity
WO2018081318A1 (en) * 2016-10-25 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use
EP3658118B1 (en) 2017-07-24 2025-03-19 Novavax, Inc. Methods and compositions for treating respiratory disease
KR20250151575A (ko) 2018-03-19 2025-10-21 노바백스, 인코포레이티드 다가 인플루엔자 나노입자 백신
CA3107083A1 (en) 2018-08-13 2020-02-20 Janssen Vaccines & Prevention B.V. Stabilized filovirus glycoprotein trimers
CN109142723B (zh) * 2018-08-21 2021-07-13 苏州华益美生物科技有限公司 人类免疫缺陷病毒快速检测测试卡及其应用
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
US20240189416A1 (en) 2020-05-11 2024-06-13 Janssen Pharmaceuticals, Inc. Stabilized coronavirus spike protein fusion proteins
EP4149538A1 (en) 2020-05-11 2023-03-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
AU2021271300A1 (en) 2020-05-11 2023-02-02 Janssen Pharmaceuticals, Inc. RNA replicon encoding a stabilized corona virus spike protein
CA3180554A1 (en) * 2020-05-29 2021-12-02 Jason MCLELLAN Engineered coronavirus spike (s) protein and methods of use thereof
CN111704657B (zh) * 2020-06-16 2021-11-09 四川安可瑞新材料技术有限公司 Hiv-2重组抗原及其制备方法、用途
JP2023532369A (ja) 2020-07-06 2023-07-27 ヤンセン ファーマシューティカルズ,インコーポレーテッド 安定化されたコロナウイルススパイクタンパク質融合タンパク質
WO2022032274A1 (en) * 2020-08-02 2022-02-10 Richard Ascione Vaccine compositions for influenza viruses and methods of use
WO2022213076A1 (en) * 2021-03-30 2022-10-06 Baylor College Of Medicine Methods and compositions for high-potency polypeptide-based protein inhibition
WO2023047348A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized corona virus spike protein fusion proteins
WO2023047349A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized coronavirus spike protein fusion proteins
WO2024061759A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized coronavirus s proteins
CN116947982B (zh) * 2023-07-12 2024-05-14 吉林大学 三条优势表位肽序列及其在流感病毒疫苗的应用
TW202527960A (zh) * 2023-09-06 2025-07-16 美商賽諾菲巴斯德公司 經修飾b型流感血球凝集素多肽及核酸及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
DK2285408T3 (en) * 2008-06-05 2019-02-04 Ablynx Nv AMINO ACID SEQUENCES AGAINST COATING PROTEINS IN A VIRUS AND POLYPEPTIDES INCLUDING THESE FOR TREATMENT OF VIRUSAL DISEASES
WO2012158613A1 (en) * 2011-05-13 2012-11-22 Novartis Ag Pre-fusion rsv f antigens
US20130122032A1 (en) * 2011-09-30 2013-05-16 Gale Smith Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus
MX357009B (es) * 2011-11-28 2018-06-22 Crucell Holland Bv Vacunas contra el virus de la influenza y sus usos.
TR201902513T4 (tr) * 2013-04-25 2019-03-21 Janssen Vaccines & Prevention Bv Stabilize edilmiş çözünebilir prefüzyon RSV F polipeptitleri.
EP2873423B1 (en) * 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US9931394B2 (en) * 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers

Similar Documents

Publication Publication Date Title
JP2018529331A5 (enExample)
JP2016199557A5 (enExample)
JP2009268467A5 (enExample)
JP2012521786A5 (enExample)
JP2015096070A5 (enExample)
JP2021505201A5 (enExample)
MX2020003176A (es) Variantes de capsides de virus adenoasociados y metodos de uso de estas.
JP2018515096A5 (enExample)
JP2018506286A5 (enExample)
JP2016052331A5 (enExample)
JP2018504412A5 (enExample)
JP2019146574A5 (enExample)
EA201890220A1 (ru) Вакцина против rsv
JP2019214579A5 (enExample)
EA201791238A1 (ru) Способы и композиции, в которых используются варианты полипептидов klotho
RU2015135890A (ru) Композиция вакцины
JP2013543499A5 (enExample)
JP2018531624A5 (enExample)
HRP20201458T1 (hr) Trimer koji stabilizira mutacije proteina omotača hiv
JP2012095652A5 (enExample)
JP2012115277A5 (enExample)
ATE552846T1 (de) Verbesserter grippeimpfstoff
RU2017132689A (ru) СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE
JP2014525439A5 (enExample)
JP2014529399A5 (enExample)